FR0000064578 - REIT

Overall **COV** gets a fundamental rating of **3** out of 10. We evaluated **COV** against 45 industry peers in the **Diversified REITs** industry. **COV** has a medium profitability rating, but doesn't score so well on its financial health evaluation. **COV** is valued correctly, but it does not seem to be growing.

In the past year **COV** was profitable.

In the past year **COV** had a positive cash flow from operations.

Of the past 5 years **COV** 4 years were profitable.

The 3 year average ROIC (**2.67%**) for **COV** is below the current ROIC(**3.09%**), indicating increased profibility in the last year.

Industry Rank | Sector Rank | ||
---|---|---|---|

ROA | -5.67% | ||

ROE | -17.83% | ||

ROIC | 3.09% |

ROA(3y)-0.05%

ROA(5y)0.81%

ROE(3y)-0.4%

ROE(5y)2.4%

ROIC(3y)2.67%

ROIC(5y)2.67%

Looking at the **Operating Margin**, with a value of **74.63%**, **COV** is in the better half of the industry, outperforming **62.79%** of the companies in the same industry.

Industry Rank | Sector Rank | ||
---|---|---|---|

OM | 74.63% | ||

PM (TTM) | N/A | ||

GM | 80.16% |

OM growth 3Y13.27%

OM growth 5Y12.19%

PM growth 3YN/A

PM growth 5YN/A

GM growth 3Y1.75%

GM growth 5Y1.65%

Compared to 5 years ago, **COV** has more shares outstanding

Compared to 1 year ago, **COV** has a worse debt to assets ratio.

The **Altman-Z score** of **COV** (**0.51**) is worse than **76.74%** of its industry peers.

A Debt/Equity ratio of **1.21** is on the high side and indicates that **COV** has dependencies on debt financing.

Looking at the **Debt to Equity ratio**, with a value of **1.21**, **COV** is doing worse than **86.05%** of the companies in the same industry.

Industry Rank | Sector Rank | ||
---|---|---|---|

Debt/Equity | 1.21 | ||

Debt/FCF | 20.25 | ||

Altman-Z | 0.51 |

ROIC/WACC0.57

WACC5.43%

A Current Ratio of **1.00** indicates that **COV** may have some problems paying its short term obligations.

The **Quick ratio** of **COV** (**0.86**) is better than **65.12%** of its industry peers.

Industry Rank | Sector Rank | ||
---|---|---|---|

Current Ratio | 1 | ||

Quick Ratio | 0.86 |

The earnings per share for **COV** have decreased by **-2.40%** in the last year.

Looking at the last year, **COV** shows a decrease in **Revenue**. The Revenue has decreased by **-9.77%** in the last year.

The **Revenue** has been decreasing by **-6.88%** on average over the past years.

EPS 1Y (TTM)-2.4%

EPS 3Y2.02%

EPS 5Y-2.53%

EPS Q2Q%-4.52%

Revenue 1Y (TTM)-9.77%

Revenue growth 3Y-4.28%

Revenue growth 5Y-6.88%

Sales Q2Q%-29.85%

Based on estimates for the next years, **COV** will show a decrease in **Earnings Per Share**. The EPS will decrease by **-2.33%** on average per year.

The **Revenue** is expected to grow by **4.42%** on average over the next years.

EPS Next Y-5.64%

EPS Next 2Y-3.43%

EPS Next 3Y-2.33%

EPS Next 5YN/A

Revenue Next Year5.94%

Revenue Next 2Y5.28%

Revenue Next 3Y4.42%

Revenue Next 5YN/A

The EPS growth rate is stable: in the next years the growth will be about the same than in the last years.

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.

Based on the **Price/Earnings** ratio of **10.67**, the valuation of **COV** can be described as reasonable.

Compared to the rest of the industry, the **Price/Earnings** ratio of **COV** indicates a rather cheap valuation: **COV** is cheaper than 86.05% of the companies listed in the same industry.

The average S&P500 **Price/Earnings** ratio is at **27.82**. **COV** is valued rather cheaply when compared to this.

The **Price/Forward Earnings** ratio is **11.30**, which indicates a very decent valuation of **COV**.

The rest of the industry has a similar **Price/Forward Earnings** ratio as **COV**.

The average S&P500 **Price/Forward Earnings** ratio is at **19.80**. **COV** is valued slightly cheaper when compared to this.

Industry Rank | Sector Rank | ||
---|---|---|---|

PE | 10.67 | ||

Fwd PE | 11.3 |

Compared to the rest of the industry, the **Enterprise Value to EBITDA** ratio of **COV** is on the same level as its industry peers.

Compared to the rest of the industry, the **Price/Free Cash Flow** ratio of **COV** indicates a somewhat cheap valuation: **COV** is cheaper than 74.42% of the companies listed in the same industry.

Industry Rank | Sector Rank | ||
---|---|---|---|

P/FCF | 9.17 | ||

EV/EBITDA | 17.41 |

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y-3.43%

EPS Next 3Y-2.33%

Compared to an average industry **Dividend Yield** of **7.22**, **COV** pays a bit more dividend than its industry peers.

Industry Rank | Sector Rank | ||
---|---|---|---|

Dividend Yield | 6.67% |

The dividend of **COV** decreases each year by **-29.38%**.

Dividend Growth(5Y)-29.38%

Div Incr Years1

Div Non Decr Years1

The earnings of **COV** are negative and hence is the payout ratio. **COV** will probably not be able to sustain this dividend level.

DP-5.14%

EPS Next 2Y-3.43%

EPS Next 3Y-2.33%

**COVIVIO**

EPA:COV (5/30/2024, 5:29:52 PM)

**47.68**

**+0.22 (+0.46%) **

Chartmill FA Rating

GICS SectorReal Estate

GICS IndustryGroupEquity Real Estate Investment Trusts (REITs)

GICS IndustryDiversified REITs

Earnings (Last)

Earnings (Next)

Inst Owners

Inst Owner Change

Ins Owners

Ins Owner Change

Market Cap4.96B

Analysts

Price Target

Dividend

Industry Rank | Sector Rank | ||
---|---|---|---|

Dividend Yield | 6.67% |

Dividend Growth(5Y)

DP

Div Incr Years

Div Non Decr Years

Ex-Date

Surprises & Revisions

EPS beat(2)

Avg EPS beat(2)

Min EPS beat(2)

Max EPS beat(2)

EPS beat(4)

Avg EPS beat(4)

Min EPS beat(4)

Max EPS beat(4)

EPS beat(8)

Avg EPS beat(8)

EPS beat(12)

Avg EPS beat(12)

EPS beat(16)

Avg EPS beat(16)

Revenue beat(2)

Avg Revenue beat(2)

Min Revenue beat(2)

Max Revenue beat(2)

Revenue beat(4)

Avg Revenue beat(4)

Min Revenue beat(4)

Max Revenue beat(4)

Revenue beat(8)

Avg Revenue beat(8)

Revenue beat(12)

Avg Revenue beat(12)

Revenue beat(16)

Avg Revenue beat(16)

PT rev (1m)

PT rev (3m)

EPS NQ rev (1m)

EPS NQ rev (3m)

EPS NY rev (1m)

EPS NY rev (3m)

Revenue NQ rev (1m)

Revenue NQ rev (3m)

Revenue NY rev (1m)

Revenue NY rev (3m)

Valuation

Industry Rank | Sector Rank | ||
---|---|---|---|

PE | 10.67 | ||

Fwd PE | 11.3 | ||

P/S | |||

P/FCF | |||

P/OCF | |||

P/B | |||

P/tB | |||

EV/EBITDA |

EPS(TTM)

EY

EPS(NY)

Fwd EY

FCF(TTM)

FCFY

OCF(TTM)

OCFY

SpS

BVpS

TBVpS

PEG (NY)N/A

PEG (5Y)N/A

Profitability

Industry Rank | Sector Rank | ||
---|---|---|---|

ROA | -5.67% | ||

ROE | -17.83% | ||

ROCE | |||

ROIC | |||

ROICexc | |||

ROICexgc | |||

OM | 74.63% | ||

PM (TTM) | N/A | ||

GM | 80.16% | ||

FCFM |

ROA(3y)

ROA(5y)

ROE(3y)

ROE(5y)

ROIC(3y)

ROIC(5y)

ROICexc(3y)

ROICexc(5y)

ROICexgc(3y)

ROICexgc(5y)

ROCE(3y)

ROCE(5y)

ROICexcg growth 3Y

ROICexcg growth 5Y

ROICexc growth 3Y

ROICexc growth 5Y

OM growth 3Y

OM growth 5Y

PM growth 3Y

PM growth 5Y

GM growth 3Y

GM growth 5Y

F-Score

Asset Turnover0.04

Health

Industry Rank | Sector Rank | ||
---|---|---|---|

Debt/Equity | 1.21 | ||

Debt/FCF | |||

Debt/EBITDA | |||

Cap/Depr | |||

Cap/Sales | |||

Interest Coverage | |||

Cash Conversion | |||

Profit Quality | |||

Current Ratio | 1 | ||

Quick Ratio | 0.86 | ||

Altman-Z |

F-Score

WACC

ROIC/WACC

Cap/Depr(3y)

Cap/Depr(5y)

Cap/Sales(3y)

Cap/Sales(5y)

Profit Quality(3y)

Profit Quality(5y)

High Growth Momentum

Growth

EPS 1Y (TTM)-2.4%

EPS 3Y2.02%

EPS 5Y

EPS Q2Q%

EPS Next Y-5.64%

EPS Next 2Y

EPS Next 3Y

EPS Next 5Y

Revenue 1Y (TTM)-9.77%

Revenue growth 3Y-4.28%

Revenue growth 5Y

Sales Q2Q%

Revenue Next Year

Revenue Next 2Y

Revenue Next 3Y

Revenue Next 5Y

EBIT growth 1Y

EBIT growth 3Y

EBIT growth 5Y

EBIT Next Year

EBIT Next 3Y

EBIT Next 5Y

FCF growth 1Y

FCF growth 3Y

FCF growth 5Y

OCF growth 1Y

OCF growth 3Y

OCF growth 5Y